© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 19, 1635-1640,
October 6, 1999
© 1999 Oxford University Press
ACCELERATED DISCOVERY |
Antiangiogenic Activity of Prostate-Specific Antigen
Affiliation of authors: EntreMed, Inc., Rockville, MD.
Correspondence to: John W. Holaday, Ph.D., EntreMed, Inc., 9640 Medical Center Dr., Rockville, MD 20850 (e-mail: johnh{at}entremed.com)
BACKGROUND: Measurement of serum levels of prostate-specific antigen (PSA) is widely used as a screening tool for prostate cancer. However, PSA is not prostate specific, having been detected in breast, lung, and uterine cancers. In one study, patients whose breast tumors had higher levels of PSA had a better prognosis than patients whose tumors had lower PSA levels. To test the hypothesis that PSA may have antiangiogenic properties, we evaluated the effects of PSA on endothelial cell proliferation, migration, and invasion, which are key steps in angiogenesis, the process by which tumors develop a blood supply. METHODS: To assess the antiproliferative effects of PSA, we treated bovine endothelial cells and human endothelial cell lines (HUVEC and HMVEC-d) with purified human PSA (0.1-10 µM) and then stimulated them with 10 ng/mL fibroblast growth factor-2 (FGF-2). Effects on FGF-2- or vascular endothelial growth factor (VEGF)-stimulated endothelial cell migration, invasion, and tube formation were measured by use of one cell line only (HUVEC). PSA was administered to mice at 9 µM for 11 consecutive days after intravenous inoculation of B16BL6 melanoma cells to assess its ability to inhibit the formation of lung colonies (i.e., metastatic tumors). RESULTS: PSA inhibited endothelial cell proliferation, migration, and invasion at IC50 (i.e., the concentration at which inhibition was 50%) values ranging from 0.3-5 µM. In addition, PSA inhibited endothelial cell responses to both angiogenic stimulators tested, FGF-2 and VEGF. In a mouse model of metastatic disease, daily PSA treatment resulted in a 40% reduction in the mean number of lung tumor nodules compared with phosphate-buffered saline treatment (two-sided P = .003). CONCLUSION: To our knowledge, this is the first report that PSA may function in tumors as an endogenous antiangiogenic protein. This function may explain, in part, the naturally slow progression of prostate cancer. Our findings call into question various strategies to inhibit the expression of PSA in the treatment of prostate cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Patane and F. Marte Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system Eur. Heart J., May 2, 2009; 30(10): 1169 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Cramer, J. Sun, S. L. Zheng, J. Xu, and D. M. Peehl Association of Prostate-Specific Antigen Promoter Genotype with Clinical and Histopathologic Features of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2451 - 2457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Niu, S. Yeh, H. Miyamoto, G. Li, S. Altuwaijri, J. Yuan, R. Han, T. Ma, H.-C. Kuo, and C. Chang Tissue Prostate-Specific Antigen Facilitates Refractory Prostate Tumor Progression via Enhancing ARA70-Regulated Androgen Receptor Transactivation Cancer Res., September 1, 2008; 68(17): 7110 - 7119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hekim, J. Leinonen, A. Narvanen, H. Koistinen, L. Zhu, E. Koivunen, V. Vaisanen, and U.-H. Stenman Novel Peptide Inhibitors of Human Kallikrein 2 J. Biol. Chem., May 5, 2006; 281(18): 12555 - 12560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T L Veveris-Lowe, M G Lawrence, R L Collard, L Bui, A C Herington, D L Nicol, and J A Clements Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells Endocr. Relat. Cancer, September 1, 2005; 12(3): 631 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Berruti, A Mosca, M Tucci, C Terrone, M Torta, R Tarabuzzi, L Russo, C Cracco, E Bollito, R M Scarpa, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease Endocr. Relat. Cancer, March 1, 2005; 12(1): 109 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Borgono, I. P. Michael, and E. P. Diamandis Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer Mol. Cancer Res., May 1, 2004; 2(5): 257 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Nam, W. W. Zhang, J. Trachtenberg, E. Diamandis, A. Toi, M. Emami, M. Ho, J. Sweet, A. Evans, M. A.S. Jewett, et al. Single Nucleotide Polymorphism of the Human Kallikrein-2 Gene Highly Correlates With Serum Human Kallikrein-2 Levels and in Combination Enhances Prostate Cancer Detection J. Clin. Oncol., June 15, 2003; 21(12): 2312 - 2319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Balk, Y.-J. Ko, and G. J. Bubley Biology of Prostate-Specific Antigen J. Clin. Oncol., January 15, 2003; 21(2): 383 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Cao, A. Lundwall, V. Gadaleanu, H. Lilja, and A. Bjartell Anti-Thrombin Is Expressed in the Benign Prostatic Epithelium and in Prostate Cancer and Is Capable of Forming Complexes with Prostate-Specific Antigen and Human Glandular Kallikrein 2 Am. J. Pathol., December 1, 2002; 161(6): 2053 - 2063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gsur, M. Preyer, G. Haidinger, T. Zidek, S. Madersbacher, G. Schatzl, M. Marberger, C. Vutuc, and M. Micksche Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk Carcinogenesis, October 1, 2002; 23(10): 1647 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Smaletz, H. I. Scher, E. J. Small, D. A. Verbel, A. McMillan, K. Regan, W. K. Kelly, and M. W. Kattan Nomogram for Overall Survival of Patients With Progressive Metastatic Prostate Cancer After Castration J. Clin. Oncol., October 1, 2002; 20(19): 3972 - 3982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Niemela, J. Lovgren, M. Karp, H. Lilja, and K. Pettersson Sensitive and Specific Enzymatic Assay for the Determination of Precursor Forms of Prostate-specific Antigen after an Activation Step Clin. Chem., August 1, 2002; 48(8): 1257 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. TOSETTI, N. FERRARI, S. DE FLORA, and A. ALBINI Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents FASEB J, January 1, 2002; 16(1): 2 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Yousef, L. G. Kyriakopoulou, A. Scorilas, S. Fracchioli, B. Ghiringhello, M. Zarghooni, A. Chang, M. Diamandis, G. Giardina, W. J. Hartwick, et al. Quantitative Expression of the Human Kallikrein Gene 9 (KLK9) in Ovarian Cancer: A New Independent and Favorable Prognostic Marker Cancer Res., November 1, 2001; 61(21): 7811 - 7818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Y. Sun, S. P. Donald, and J. M. Phang Testosterone and prostate specific antigen stimulate generation of reactive oxygen species in prostate cancer cells Carcinogenesis, November 1, 2001; 22(11): 1775 - 1780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Migita, Y. Oda, S. Naito, W. Morikawa, M. Kuwano, and M. Tsuneyoshi The Accumulation of Angiostatin-like Fragments in Human Prostate Carcinoma Clin. Cancer Res., September 1, 2001; 7(9): 2750 - 2756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-M. Xue, G. A. Coetzee, R. K. Ross, R. Irvine, L. Kolonel, B. E. Henderson, and S. A. Ingles Genetic Determinants of Serum Prostate-specific Antigen levels in Healthy Men from a Multiethnic Cohort Cancer Epidemiol. Biomarkers Prev., June 1, 2001; 10(6): 575 - 579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Yousef and E. P. Diamandis The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease Endocr. Rev., April 1, 2001; 22(2): 184 - 204. [Abstract] [Full Text]
|
|
|
|
|
|
G. M. Yousef, A. Magklara, A. Chang, K. Jung, D. Katsaros, and E. P. Diamandis Cloning of a New Member of the Human Kallikrein Gene Family, KLK14, Which Is Down-Regulated in Different Malignancies Cancer Res., April 1, 2001; 61(8): 3425 - 3431. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. I. Izawa and C. P.N. Dinney The role of angiogenesis in prostate and other urologic cancers: a review Can. Med. Assoc. J., March 1, 2001; 164(5): 662 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Bok, S. Halabi, D. T. Fei, C. R. Rodriquez, D. F. Hayes, N. J. Vogelzang, P. Kantoff, M. A. Shuman, and E. J. Small Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Urine Levels as Predictors of Outcome in Hormone-refractory Prostate Cancer Patients: A Cancer and Leukemia Group B Study Cancer Res., March 1, 2001; 61(6): 2533 - 2536. [Abstract] [Full Text]
|
|
|
|
|
|
E. P. Diamandis Prostate-specific Antigen: A Cancer Fighter and a Valuable Messenger? Clin. Chem., July 1, 2000; 46(7): 896 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Yousef, A. Chang, and E. P. Diamandis Identification and Characterization of KLK-L4, a New Kallikrein-like Gene That Appears to be Down-regulated in Breast Cancer Tissues J. Biol. Chem., April 14, 2000; 275(16): 11891 - 11898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Hartford, T. Gohongi, D. Fukumura, and R. K. Jain Irradiation of a Primary Tumor, Unlike Surgical Removal, Enhances Angiogenesis Suppression at a Distal Site: Potential Role of Host-Tumor Interaction Cancer Res., April 1, 2000; 60(8): 2128 - 2131. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. A. Khan Re: Antiangiogenic Activity of Prostate-Specific Antigen J Natl Cancer Inst, February 16, 2000; 92(4): 345 - 345. [Full Text] [PDF]
|
|
|
|
|
|
A. H. Fortier, D. K. Grella, B. J. Nelson, and J. W. Holaday RESPONSE: Re: Antiangiogenic Activity of Prostate-Specific Antigen J Natl Cancer Inst, February 16, 2000; 92(4): 345a - 346a. [Full Text] [PDF]
|
|